We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
+1.58%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$251M
AUM Growth
-$32.1M
Cap. Flow
-$32.3M
Cap. Flow %
-12.88%
Top 10 Hldgs %
68.46%
Holding
112
New
6
Increased
15
Reduced
10
Closed
13

Top Buys

1
DCGO icon
DocGo
DCGO
+$3.77M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.73M
3
VRNA
Verona Pharma
VRNA
+$1.28M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$803K
5
MREO
Mereo BioPharma
MREO
+$667K

Top Sells

1
FTAI icon
FTAI Aviation
FTAI
+$16.8M
2
WEST icon
Westrock Coffee
WEST
+$4.89M
3
CLOZ icon
Panagram BBB-B CLO ETF
CLOZ
+$4.73M
4
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$3.64M
5
LGND icon
Ligand Pharmaceuticals
LGND
+$2.39M

Sector Composition

1 Healthcare 30.74%
2 Materials 28.51%
3 Financials 14.16%
4 Communication Services 8.23%
5 Technology 1.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LK
26
DELISTED
Luckin Coffee Inc. American Depositary Shares
LK
$2.11M 0.84%
100,000
– –
BCRX icon
27
BioCryst Pharmaceuticals
BCRX
$2.32B
$1.94M 0.77%
+314,307
New +$1.73M
XERS icon
28
Xeris Biopharma Holdings
XERS
$1.52B
$1.84M 0.74%
820,000
+220,000
+37% +$443K
PTGX icon
29
Protagonist Therapeutics
PTGX
$8.89B
$1.81M 0.72%
52,368
– –
AB icon
30
AllianceBernstein
AB
$3.55B
$1.66M 0.66%
49,000
– –
VRTX icon
31
Vertex Pharmaceuticals
VRTX
$124B
$1.41M 0.56%
3,000
– –
XBI icon
32
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$1.3M 0.52%
14,000
-2,000
-13% -$179K
RHP icon
33
Ryman Hospitality Properties
RHP
$7.91B
$1.2M 0.48%
12,000
– –
EOLS icon
34
Evolus
EOLS
$375M
$1.18M 0.47%
108,682
+28,682
+36% +$353K
MDLZ icon
35
Mondelez International
MDLZ
$79.6B
$916K 0.37%
14,000
– –
ABBV icon
36
AbbVie
ABBV
$457B
$864K 0.34%
5,037
– –
MREO
37
Mereo BioPharma
MREO
$49.8M
$850K 0.34%
236,000
+206,000
+687% +$667K
KMB icon
38
Kimberly-Clark
KMB
$36.4B
$829K 0.33%
6,000
– –
EDIT icon
39
Editas Medicine
EDIT
$448M
$827K 0.33%
177,000
+37,000
+26% +$209K
XENE icon
40
Xenon Pharmaceuticals
XENE
$6.64B
$814K 0.32%
20,866
-3,000
-13% -$120K
DD icon
41
DuPont de Nemours
DD
$18.3B
$799K 0.32%
7,911
– –
MSFT icon
42
Microsoft
MSFT
$2.89T
$715K 0.29%
1,600
– –
ROIV icon
43
Roivant Sciences
ROIV
$24.9B
$666K 0.27%
63,000
+9,800
+18% +$107K
CTVA icon
44
Corteva
CTVA
$58.7B
$624K 0.25%
11,563
– –
CNQ icon
45
Canadian Natural Resources
CNQ
$90.5B
$598K 0.24%
16,800
– –
DOW icon
46
Dow Inc
DOW
$21.6B
$591K 0.24%
11,136
– –
BBIO icon
47
BridgeBio Pharma
BBIO
$16B
$532K 0.21%
21,000
+5,000
+31% +$137K
AAPL icon
48
Apple
AAPL
$4.9T
$525K 0.21%
2,494
– –
CLOX icon
49
Panagram AAA CLO ETF
CLOX
$309M
$500K 0.2%
19,572
-73,384
-79% -$1.87M
KO icon
50
Coca-Cola
KO
$358B
$484K 0.19%
7,600
– –
1
2
3 4 5

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
TT
TI-Trust Quincy, Illinois $168M AUM 24.32% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return

David M. Knott Jr's Q2 2024 Portfolio in Review

As of Q2 2024, David M. Knott Jr held 112 positions worth $251M, down 11% from $283M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

David M. Knott Jr withdrew a net $32.3M in Q2 2024, closing 13 positions and reducing 10 holdings. Its most notable exit was FTAI Aviation, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 30% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in BioCryst Pharmaceuticals worth $1.94M.

  • David M. Knott Jr's largest Q2 2024 buy was BioCryst Pharmaceuticals: 314,307 shares worth $1.94M.
  • David M. Knott Jr added most to DocGo in Q2 2024, an estimated $3.77M increase.
  • David M. Knott Jr's biggest Q2 2024 reduction was Panagram BBB-B CLO ETF, cutting an estimated $4.73M.
  • David M. Knott Jr fully exited FTAI Aviation in Q2 2024, selling an estimated $16.8M.
  • David M. Knott Jr's ten largest holdings make up 68% of its $251M portfolio in Q2 2024.
  • David M. Knott Jr opened 6 new positions and closed 13 in Q2 2024.
  • David M. Knott Jr's portfolio value fell 11% quarter-over-quarter to $251M.

Based on David M. Knott Jr's 13F filing for Q2 2024, filed 12 Aug 2024.